In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors
Most antiretroviral medical treatments were developed and tested principally on HIV-1 B nonrecombinant strain, which represents less than 10% of the worldwide HIV-1-infected population. HIV-1 circulating recombinant form CRF02_AG is prevalent in West Africa and is becoming more frequent in other cou...
Saved in:
| Main Authors: | Xiaoju Ni, Safwat Abdel-Azeim, Elodie Laine, Rohit Arora, Osamuede Osemwota, Anne-Geneviève Marcelin, Vincent Calvez, Jean-François Mouscadet, Luba Tchertanov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Virology |
| Online Access: | http://dx.doi.org/10.1155/2012/548657 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors
by: Daniele Armenia, et al.
Published: (2025-06-01) -
From protease inhibitors to integrase strand transfer inhibitors: the evolution of HIV drug resistance management
by: HU Zhiliang, YANG Yongfeng
Published: (2025-01-01) -
Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China
by: Huizheng Zhang, et al.
Published: (2023-12-01) -
Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors
by: Yen-Wen Chen, et al.
Published: (2020-07-01) -
Exploring Zinc C295 as a Dual HIV-1 Integrase Inhibitor: From Strand Transfer to 3′-Processing Suppression
by: Sharif Karim Sayyed, et al.
Published: (2024-12-01)